Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Dec;83(12):2835-2838.
doi: 10.1111/bcp.13310. Epub 2017 May 16.

Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum: a case report

Catia Marzolini  1 , Laurent Decosterd  2 , Ursula Winterfeld  3 , Frédéric Tissot  4 , Katyuska Francini  5 , Thierry Buclin  3 , Françoise Livio  3
Affiliations
Case Reports

Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum: a case report

Catia Marzolini et al. Br J Clin Pharmacol. 2017 Dec.
No abstract available

Keywords: cobicistat; elvitegravir; free concentrations; pharmacokinetics; pregnancy; total concentrations.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Total and free elvitegravir (EVG) and cobicistat (cobi) plasma concentrations in a patient during pregnancy and postpartum (closed circles: EVG; open triangles: cobi; continuous lines: total concentrations; dashed lines: free concentrations). The threshold lines represent the EVG concentration inhibiting viral suppression by 95% (IC95 = 45 ng ml–1) and the EVG concentration producing a 90% effective response (EC90 = 0.53 ng ml–1)
See this image and copyright information in PMC

Comment in

References

    1. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP, et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 2016; 44 (Database Issue): D1054–D1068. - PMC - PubMed
    1. Aouri M, Calmy A, Hirschel B, Telenti A, Buclin T, Cavassini M, et al. A validated assay by liquid chromatography‐tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients. J Mass Spectrom 2013; 48: 616–625. - PubMed
    1. Fayet A, Béguin A, de Tejada BM, Colombo S, Cavassini M, Gerber S, et al. Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction. Ther Drug Monit 2008; 30: 511–522. - PubMed
    1. Schalkwijk S, Colbers A, Konopnicki D, Greupink R, Russel FG, Burger D, et al. PANNA network . First reported use of elvitegravir and cobicistat during pregnancy. AIDS 2016; 30: 807–808. - PubMed
    1. Podany AT, Scarsi KK, Fletcher CV. Comparative clinical pharmacokinetics and pharmacodynamics of HIV‐1 integrase strand transfer inhibitors. Clin Pharmacokinet 2017; 56: 25–40. - PMC - PubMed

Publication types

MeSH terms

Substances